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Background: Endothelial dysfunction plays a central and critical role in the initiation and
development of idiopathic pulmonary arterial hypertension (IPAH), and a variety of
evidence suggests that endothelial progenitor cells (EPCs) constitute one aspect of
endothelium repair. In addition, transplantation of EPCs could attenuate pulmonary
hypertension induced by monocrotaline in rats. However, it has not been examined and
reported whether circulating EPCs from patients with IPAH are damaged.
Methods: EPCs were isolated and cultured from patients with IPAH (n ¼ 20) and matched
healthy volunteers (n ¼ 20). Circulating EPC numbers (enumerated as AC133+KDR+ cells)
as well as migratory and adhesive activity were assessed. Blood levels of vascular
endothelial growth factor (VEGF), homocysteine (Hcy), B-type natriuretic peptide (BNP),
von Willebrand Factor (vWF) and interleukin-6 (IL-6) were also measured.
Results: A signiﬁcant decrease was observed in circulating EPC (AC133+KDR+ cells,
86.6720.7 cells/ml blood vs. 119.6725.4 cells/ml blood, Po0.001) numbers and the cell
numbers expanded in vitro (47.2714.5 vs. 70.7715.2 EPCs/ 200 ﬁeld; Po0.001) in
patients with IPAH. EPCs from patients with IPAH were signiﬁcantly impaired in their
migratory capacity and ability to adhere to ﬁbronectin. Blood levels of VEGF, Hcy, BNP, vWF
and IL-6 were elevated in patients with IPAH. EPC numbers and activity were inversely
related to Hcy, IL-6, BNP and vWF.
Conclusions: Our observations indicated that EPC numbers and functional capacity were
impaired in patients with IPAH, which might not only give potential insight into theElsevier Ltd. All rights reserved.
1 87236889/86 571 87236500; fax:+86 571 87236889.
oo.com.cn (W. XingXiang), chenjz01@163.com (C. JunZhu).
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Z. JunHui et al.1074pathophysiological mechanisms but also might be useful for identifying suitable
therapeutic targets in these patients.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a rare
disorder of unknown etiology characterized by raised
pulmonary artery pressures with pathological changes in
precapillary pulmonary arteries. The disease was rapidly
progressive, leading to right heart failure and death in a
median of 2.8 years from diagnosis before the availability of
disease-speciﬁc (targeted) therapy through the mid-
1980s.1–3 Modern treatment has markedly improved physical
function and has extended survival, and the 5-year mortality
rate is 50%.4 However, we still do not understand what
initiates the disease or what allows it to progress.
Although the speciﬁc mechanisms responsible for the
development of IPAH remain unknown, a number of mecha-
nisms have been proposed. The histopathologic features of
IPAH suggest that endothelial injury and proliferative stimuli
are fundamental processes. Abnormal bone morphogenetic
protein receptor-type II (BMPR2) may play an important role
in the pathogenesis of IPAH, with over 25% of patients with
IPAH having abnormal BMPR2 structure or function.5–7 The
BMPR2 pathway induces apoptosis in some types of cells, and
the abnormal pathway activity also permits excessive
endothelial cell growth and proliferation in response to a
variety of injuries.8–12 Additional studies have demonstrated
abnormalities in other pathways that may contribute to the
pathogenesis of IPAH. These include enhanced expression of
the serotonin transporter, diminished expression of the
enzymes responsible for synthesis of nitric oxide (NO) and
prostacyclin, altered potassium channels, and increased
production of several growth factors, including endothelin,
vascular endothelial growth factor, and platelet-derived
growth factor.13,14
In particular, dysfunction of the endothelium was thought
to play a central and critical role in the initiation and
development of IPAH.15,16 Endothelial dysfunction ulti-
mately represents a balance between the magnitude of
injury and the capacity for repair.17 A variety of evidence
suggests that endothelial progenitor cells (EPCs) constitute
one aspect of this repair process.17,18 EPCs are a cell
population that have the capacity to circulate, proliferate,
and differentiate into mature endothelial cells, but have
neither acquired characteristic mature endothelial markers
nor formed a lumen.19–21 These cells co-express hemato-
poietic stem/progenitor cell markers (CD34 or AC133) as
well as endothelial markers (VE-Cadherin or VEGFR-2).19–23
Laboratory evidence suggests that these precursors partici-
pate in postnatal neovascularization and re-endothelializa-
tion.17–19,24–26
Recently, experimental data suggested that transplanta-
tion of EPCs attenuated monocrotaline-induced pulmonary
hypertension in the rat model.27,28 Moreover, Takahashi
et al.29 reported that transplantation of autologous EPCs
gave signiﬁcant improvements in mean pulmonary artery
pressure, cardiac output, and pulmonary vascular resistance
in the dog dehydromonocrotaline model.On the basis of these considerations, we hypothesized
that circulating EPCs from patients with IPAH might be
damaged, which is associated with endothelial dysfunction
and could promote the disease progression. To test this
hypothesis, the numbers and activity of EPCs from periph-
eral blood of patients with IPAH were determined in the
present study, which has not been previously examined and
reported.Materials and methods
Characteristics of the patients and controls
Twenty IPAH patients were consecutively enrolled. The
control group comprised 20 healthy volunteers who were
matched as to gender and age with the patients, and clinical
evaluation has been done to be sure about healthy status of
control group. Ethics committee approval was obtained, as
was informed consent from patients and controls. Table 1
shows the clinical details of the studied population. IPAH
was deﬁned as pulmonary hypertension unexplained by any
secondary cause, on the basis of the criteria of the National
Institutes of Health registry.30 The diagnosis of IPAH was
based on clinical assessment, right heart catheterization,
echocardiography, spiral-computed tomography of the
pulmonary arteries, pulmonary angiography, ventilation/
perfusion lung scan, and complete lung function testing.
Pulmonary hypertension as a result of heart disease,
pulmonary disease, sleep-associated disorders, chronic
thromboembolic disease, autoimmune or collagen vascular
disease, HIV infection, liver disease was excluded. All
participants were all free of wounds, ulcers, retinopathy,
recent surgery, inﬂammatory or malignant disease that may
inﬂuence EPCs kinetics.
At the beginning of each experimental session, a clinical
evaluation including 6-min walk test was performed, and
24 h after 6-min walk test venous blood was collected for
measurement of laboratory variables, isolation of EPC, and
ﬂow cytometric analysis during catheterization.The exercise capacity and hemodynamics
The 6-min walk test was performed in all subjects using a
standardized protocol in accordance to the American
Thoracic Society statement 2002.31 Patients walked along
an enclosed-level corridor, and length to ﬁrst turnaround
point was 40m. Technicians did not escort but encouraged
patients using standard phrases such as ‘‘You are going
well,’’ ‘‘Keep up the good work,’’ and were instructed not
to use other encouragement. All patients were told to use
their own pace, but to cover as much ground as possible in
6min.
In IPAH patients a Swan-Ganz catheter (Arrow Deutsch-
land Gmbh, Erding, Germany) and an arterial catheter
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Table 1 Characteristics of patients with IPAH and control subjects.
Characteristics IPAH (n ¼ 20) Control (n ¼ 20) P value
Age, year 36.6711.4 37.3710.8 NS
Sex, no.
Male 6 5 NS
Female 14 15 NS
Duration of symptoms, months 25710
Total cholesterol, mmol/L 4.570.8 4.770.7 NS
Triglycerides, mmol/L 1.270.5 1.170.4 NS
Medication, no.
Anticoagulant agents 18
Calcium antagonists 13
Nitrates 7
Digitalis 4
Diuretics 1
Biomakers
VEGF, pg/mL 603.4788.5 305.5775.6 Po0.001
BNP, pg/mL 151.7751 19.278.6 Po0.001
IL-6, pg/mL 5.3371.07 1.7570.69 Po0.001
vWF, % 215745 110727 Po0.001
Hcy, mmol/L 19.475.7 12.973.8 Po0.001
The 6-min walk distance, m 257742 586780 Po0.001
Mean pulmonary artery pressure, mmHg 5879
Pulmonary vascular resistance, dyn s cm5 10677220
Cardiac output, L/min 3.770.6
Pulmonary function
SaO2, % 9374
SvO2, % 6175
FVC, % predicted 8576
FEV1, % predicted 7373
SaO2 indicates arterial oxygen pressure; SvO2, mixed venous oxygen saturation; FVC, forced vital capacity; and FEV1, forced expiratory
volume in 1 s. Data are mean7SD.
Endothelial progenitor cells and IPAH 1075(Angiocath, BD) were inserted into the right internal jugular
and right radial artery, respectively. Hemodynamic mea-
surements were performed in recumbent position. Contin-
uous monitoring included heart rate, systemic and
pulmonary artery blood pressures and transcutaneous
oxygen saturation. Additional parameters were pressures
in wedge position and right atrium. Cardiac output was
obtained, using triplicate measurements with the thermo-
dilution method (Agilent, Boeblingen, Germany). Pulmonary
vascular resistance (PVR) and systemic vascular resistance
(SVR) were calculated according to the standard formulas as
follows.32
PVR ¼ 80 (mean pulmonary artery pressure [mmHg]–
pulmonary capillary wedge pressure [mm Hg])/cardiac
output[L/min]
and
SVR ¼ 80 (mean systemic artery pressure[mmHg]–right
atrial pressure[mmHg])/cardiac output[L/min] deﬁned in
dyns/cm5
Both the walk test and right heart catheterization were
administered by personnel who were unaware of the study
protocol.Isolation, cultivation and characterization of
circulating EPCs
EPCs were isolated, cultured and characterized according to
previously described techniques.17,33–36 Brieﬂy, mononuc-
lear cells (MNCs) were isolated from peripheral blood of
patients with IPAH or control subjects by Ficoll density
gradient centrifugation and cultured on ﬁbronectin
(Chemicon)-coated dishes in Medium 199 (Sigma) supple-
mented with 10% fetal-calf serum and vascular endothelial
growth factor (VEGF, 50 ng/ml, Chemicon). After 4 days in
culture, adherent cells were incubated with DiLDL
(Molecular Probe) and stained with FITC-labeled Ulex
europaeus agglutinin (UEA-1; Sigma). After the staining,
samples were viewed with an inverted ﬂuorescent micro-
scope (Leica) and further demonstrated by laser scanning
confocal microscope (LSCM, Leica). Cells demonstrating
double-positive ﬂuorescence were identiﬁed as differentiat-
ing EPCs.33,35,36 Two or three independent investigators
evaluated the number of EPCs per well by counting 15
randomly selected high-power ﬁelds ( 200) with an
inverted ﬂuorescent microscope.
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For ﬂow cytometric determination of circulating EPCs
(AC133+/KDR+), 100 mL of whole blood was labeled for
30min at 4 1C using manufacturer-recommended concen-
trations with antihuman-KDR-PE (Becton Dickinson) and
antihuman-AC133-APC (Miltenyi Biotec). Fluorescent iso-
type-matched antibodies (Becton Dickinson) were used as
controls. The suspension was then incubated with ﬂuores-
cence-activated cell sorter (FACS) lysing solution (Becton-
Dickinson) according to the manufacturer’s instructions for
10–15min. After washing and ﬁxation, samples were
analyzed on a FACS—Calibur Instrument (Becton-Dickinson).
Surface markers AC133 and KDR were determined on cells in
the lymphocyte gate, because this is where EPCs are
commonly found.33 The percentages of positive cells were
converted to cells per mL of blood using the complete blood
count.33,37,38Migration assay
EPCs migration was evaluated by using a modiﬁed Boyden
chamber assay (Jiangsu Qilin medical equipment factory,
China). In brief, isolated EPCs were detached using 1mmol/
L EDTA in PBS (pH 7.4), harvested by centrifugation,
resuspended in 500 mL M199, and counted, then 2 104
EPCs were placed in the upper chamber of a modiﬁed
Boyden chamber. M199 and human recombinant VEGF
(50 ng/mL) were placed in the lower compartment of the
chamber. After 24 h incubation at 37 1C, the lower side of
the ﬁlter was washed with PBS and ﬁxed with 2%
paraformaldeyde. For quantiﬁcation, cells were stained
with Giemsa solution. Cells migrating into the lower
chamber were counted manually in three random micro-
scopic ﬁelds ( 200).33,35,38Cell adhesion assay
Human EPCs were washed with PBS and gently detached
with 1mmol/L EDTA in PBS. After centrifugation and
resuspension in M199, 5%FBS, identical cell numbers were
replated onto ﬁbronectin-coated culture dishes and incu-
bated for 30min at 37 1C. Adherent cells were counted by
independent-blinded investigators.18,35,38VEGF, homocysteine, B-type natriuretic peptide,
von Willebrand factor, and interleukin-6
Blood levels of VEGF and interleukin-6 (IL-6) were measured
by ELISA (R&D), according to the manufacturer’s instruc-
tions. Plasma total homocysteine (Hcy) was measured using
an automated ﬂuorescence polarization immunoassay on an
IMx Analyser as described previously.38,39 Von Willebrand
factor (vWF) concentrations were measured by enzyme
immunoassay for the assessment of endothelial cell dysfunc-
tion. B-type natriuretic peptide (BNP) was measured by the
Triage BNP test (Biosite, San Diego, CA).40Statistical analysis
All values were expressed as mean7SD. Student’s unpaired
t test was performed for comparison of data between two
groups. Categorical variables were compared by means of
the w2 test. Correlations were tested by Pearson analysis.
Values of Po0.05 were considered signiﬁcant. All statistical
analyses were performed with SPSS 12.0.
Results
Blood levels of VEGF, Hcy, BNP, vWF and IL-6 in
patients with IPAH
Blood levels of VEGF, Hcy, vWF and IL-6 were elevated in
patients with IPAH (Table 1).
EPC levels in patients with IPAH
The number of EPCs in the peripheral blood was assayed via
ﬂuorescence-activated cell sorter analysis, which might
more closely resemble the in vivo conditions. Circulating
EPCs were enumerated as AC133+KDR+ cells.21–23,37 A
signiﬁcant decrease was observed in circulating EPCs in
subjects with IPAH compared with matched control subjects
(86.6720.7 vs. 119.6725.4 cells/mL, Po0.001, Figure 1),
AC133+KDR+ cells correlated to the 6-min walk distance
(6MWD, r ¼ 0.71, Po0.001, n ¼ 40), BNP (r ¼ 0.6,
Po0.001, n ¼ 40), vWF (r ¼ 0.68, Po0.001, n ¼ 40), IL-6
(r ¼ 0.59, Po0.001, n ¼ 40), Hcy (r ¼ 0.59, Po0.001,
n ¼ 40), mPAP (r ¼ 0.53, Po0.05, n ¼ 20), and PVR
(r ¼ 0.45, Po0.05, n ¼ 20). In addition, EPCs were
expanded from human blood in vitro and identiﬁed by DiLDL
uptake and lectin staining. EPC numbers decreased in
subjects with IPAH compared with matched control subjects
after ex vivo cultivation (47.2714.5 vs. 70.7715.2 EPCs/
 200 ﬁeld; Po0.001, Figure 2). Differentiating EPCs also
correlated to 6MWD (r ¼ 0.65, Po0.001, n ¼ 40), BNP
(r ¼ 0.63, Po0.001, n ¼ 40), vWF (r ¼ 0.61, Po0.001,
n ¼ 40), IL-6 (r ¼ 0.64, Po0.001, n ¼ 40), and Hcy
(r ¼ 0.52, P ¼ 0.001, n ¼ 40).
Migratory capacity of EPCs in patients with IPAH
To assess the functional activity of EPCs, migration of
isolated EPC in response to VEGF was determined using a
modiﬁed Boyden chamber. As illustrated in Figure 3, the
migratory capacity of EPCs isolated from patients with
IPAH was signiﬁcantly impaired compared with healthy
matched volunteers (12.575.0 vs. 20.577.4 cells/ 200
ﬁelds, Po0.001, Figure 3). The migratory capacity of EPCs
correlated to 6MWD (r ¼ 0.63, Po0.001, n ¼ 40), BNP
(r ¼ 0.52, P ¼ 0.001), vWF (r ¼ 0.55, Po0.001, n ¼
40), IL-6 (r ¼ 0.56, Po0.001, n ¼ 40), and Hcy (r ¼ 0.53,
Po0.001, n ¼ 40).
EPCs adhesion of EPCs in patients with IPAH
We assessed the adhesion of EPCs, because adhesion to the
extracellular matrix is believed to be important during new
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Figure 2 Differentiated EPC levels in patients with IPAH. EPCs
were expanded from human blood in vitro and identiﬁed by DiI-
acLDL uptake and lectin staining. EPCs were signiﬁcantly
reduced in subjects with IPAH compared with control subjects
after ex vivo cultivation. *Po0.001 vs. control.
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Figure 3 Migratory capacity of endothelial progenitor cells
was signiﬁcantly impaired in patients with IPAH. *Po0.001 vs.
control.
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Figure 4 Endothelial progenitor cells from patients with IPAH
exhibited a signiﬁcant decrease in the number of adhesiveness
cells. *Po0.001 vs. control.
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Figure 1 Circulating EPC levels in patients with IPAH.
Circulating EPCs were enumerated as AC133+KDR+ cells by ﬂow
cytometry in the lymphocyte gate. Circulating EPCs number
signiﬁcantly decreased in subjects with IPAH compared with
matched control subjects. *Po0.001 vs. control.
Endothelial progenitor cells and IPAH 1077blood vessel growth. EPCs from patients with IPAH were
found to be signiﬁcantly impaired in their ability to adhere
to ﬁbronectin (24.277.2 vs. 38.978.0, Po0.001, Figure 4).
The ability of EPCs adhesion correlated to 6MWD (r ¼ 0.69,
Po0.001, n ¼ 40), BNP (r ¼ 0.59, Po0.001, n ¼ 40), vWF
(r ¼ 0.63, Po0.001, n ¼ 40), IL-6 (r ¼ 0.71, Po0.001,
n ¼ 40), and Hcy (r ¼ 0.43, P ¼ 0.006, n ¼ 40).Discussion
To the best of our knowledge, this is the ﬁrst study to
examine the number and activity of EPCs from peripheral
blood of patients with IPAH. We observed that the number of
differentiated EPCs and AC133-/KDR-positive circulating
EPCs was signiﬁcantly reduced in subjects with IPAH. Inaddition, the functional activities of isolated EPCs such as
migratory and adhesive capacity were also impaired.
Therefore, an autologous application/transplantation or a
pharmacological mobilization/activation of EPCs might be
future possibilities for the treatment of IPAH.
Recently, Nagaya et al.27 have reported transplantation of
EPCs modestly attenuated monocrotaline-induced pulmon-
ary hypertension in nude rats (16% decrease in pulmonary
vascular resistance). Furthermore, very recent results from
the Stewart group show near-complete prevention of
pulmonary hypertension in the rat monocrotaline model
using syngeneic bone marrow—derived EPCs.28 In addition,
in experimental dogs with dehydromonocrotaline-induced
pulmonary hypertension, transplantation of autologous EPCs
from peripheral blood gave signiﬁcant improvements in
mean pulmonary artery pressure, cardiac output, and
pulmonary vascular resistance.29 More recently, we have
demonstrated that intravenous infusion of autologous EPCs
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effects on exercise capacity and pulmonary hemodynamics
in adults with IPAH.41 Thus, the results of the present study
seem consistent with current efforts to ameliorate pulmon-
ary hypertension by augmentation of circulating EPCs.
Pulmonary vascular endothelial dysfunction was thought
to play a major role in the initiation and development of
IPAH.15,16 This endothelial dysfunction ultimately represents
an imbalance between the magnitude of injury and the
capacity for repair.17 There is strong evidence that EPCs may
play an important role in endothelium maintenance, being
implicated in both re-endothelialization and neovascular-
ization.17–19,24–26 In this study, we have observed that
circulating vWF levels were signiﬁcantly higher in patients
IPAH, which reﬂect the severity of endothelial injury and
dysfunction, and it inversely correlated with EPC numbers
and functional capacity. Therefore, the reduction in the
number of EPCs and their functional impairment may
contribute to an insufﬁcient regeneration of the endothe-
lium, which is associated with endothelial dysfunction.
Migration is essential for stem/progenitor cells to invade
the sites of injured vessels or the ischemic tissue, which
might reﬂect their homing capacity.33 In this study, we
observed EPCs isolated from patients with IPAH exhibited a
decreased migration in response to VEGF. The reduced
response to VEGF might be due to a downregulation of the
VEGF receptor KDR, or/and defects in the downstream
signaling pathway.33 However, atleast the expression of the
KDR receptor was not reduced in EPCs derived from patients
with IPAH compared with those from matched volunteers
(data not shown), suggesting that defects in the downstream
signaling pathways might be responsible for the impairment
of cell migration. Future studies will be needed to address
this question. The impaired response of EPCs to VEGF in IPAH
patients might be responsible for the paradoxical phenom-
enon between the alteration in endothelial function and the
elevated level of VEGF.42 In addition, this might also explain
the paradoxical phenomenon between reduced number and
activity of circulating EPCs and the elevated level of VEGF,
which was observed in this study, since VEGF has been shown
to promote the mobilization of EPCs.
An additional interesting ﬁnding in our study is the
reduced capacity of circulating EPCs from patients with
IPAH to adhere to ﬁbronectin. This observation, which may
be related to a dysregulated integrin synthesis,43 can also
aid in explaining the reduction in EPCs number and
endothelial dysfunction evident in patients with IPAH, for
the adhesive capacity of EPCs is thought to be important in
EPCs mobilization and homing.
Although the mechanisms by which circulating EPC
numbers and activity were impaired in IPAH patients remain
to be uncertain to date, there are several possible scenarios
which could account for the damaged EPCs. Firstly, our
ﬁnding of a negative correlation between the IL-6 level and
the number and activity of EPCs over the entire study group
may support the hypothesis that the individual microin-
ﬂammatory state is related to the number of circulating
EPC. Furthermore, it is known from in vitro experiments
that C reactive protein (CRP) attenuates EPC survival and,
recently, it has been demonstrated that CRP has the
potential to decrease the angiogenic function of EPC.44,45
However, hsCRP was not signiﬁcantly increased in the serumof IPAH patients (data not shown). Secondly, the reduced
number and activity of circulating EPCs in patients with IPAH
might be associated with hyperhomocysteinemia. Arroliga
et al.46 have reported that IPAH patients are signiﬁcantly
more likely to have hyperhomocysteinemia. In this study, we
also have observed that plasma total Hcy levels of IPAH
patients are signiﬁcantly higher than that of controls, and
there is an inverse correlation between the number and
activity of EPCs and Hcy levels. Moreover, we previously
reported that homocysteine dose and time dependently
decreased EPC numbers and impaired the cells proliferation,
migration, adhesion and in vitro vasculogenesis capacity.24
Lastly, the continuous endothelial damage or dysfunction
may lead to an eventual depletion or exhaustion of a
presumed ﬁnite supply of EPCs.
Obviously, because of the limitations imposed by studying
patients, we cannot determine the molecular pathway(s)
responsible for impairment in circulating EPCs in our
patients with IPAH. Future studies will be needed to address
this question. The second limitation of this pilot trial is a
relatively small quantity of patients with IPAH enrolled in
this study. Future studies on a larger scale will be required
to perform.
Taken together, the present study demonstrated that
EPCs could play a role in patients with IPAH, which might not
only give potential insight into the pathophysiological
mechanisms but might be useful for identifying suitable
therapeutic targets in these patients. However, further
studies are needed to deﬁne the mechanisms that underlie
the reduction in the number and activity of circulating EPCs
in patients with IPAH.Conﬂict of interest statement
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